We provide you with 20 years of free, institutional-grade data for NKTR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NKTR. Explore the full financial landscape of NKTR stock.
| Reported Date | CIK | Ticker | Type |
|---|
Nektar Therapeutics(NASDAQ:NKTR) 
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic...
Website: http://www.nektar.com
Founded: 1990
Full Time Employees: 723
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about NKTR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.